Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies
- 1 April 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (7), 1193-1194
- https://doi.org/10.1200/jco.2003.12.072
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup TrialJournal of Clinical Oncology, 2003
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2000
- SYSTEMIC THERAPY FOR RENAL CELL CARCINOMAJournal of Urology, 2000
- Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell CancerJournal of Clinical Oncology, 1999
- Novel mutations of the MET proto-oncogene in papillary renal carcinomasOncogene, 1999
- Interferon-α and survival in metastatic renal carcinoma: early results of a randomised controlled trialThe Lancet, 1999
- Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 1998
- Prospective Randomized Trial of High-Dose Interleukin-2 Alone or in Conjunction With Lymphokine-Activated Killer Cells for the Treatment of Patients With Advanced CancerJNCI Journal of the National Cancer Institute, 1993
- High-Dose Recombinant Interleukin-2 Alone: A Regimen With Limited Activity in the Treatment of Advanced Renal Cell CarcinomaJNCI Journal of the National Cancer Institute, 1990